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Conformational plasticity and flexibility are key structural features of ApoAI
in lipid metabolism. Amyloidogenic single point mutations, associated with
incurable familial amyloidosis with fibril deposition in peripheral organs, may
have a dramatic impact on the structural and functional features of ApoAI.
Here, the consistent body of data on ApoAI variants has been reviewed, with
the aim of highlighting the hallmarks of the pathology. In accordance with our
observations, as well as that of others, we propose a model that accounts for the
alteration of the delicate balance between lipid-free/lipid-bound dynamic states
which is based on monomer-to-dimer interconversion via domain swapping.
Keywords: aggregation; amyloidosis; Apolipoprotein A-I; conformational
diseases; domain swapping; protein misfolding
The natural protein and its
physiological role
Apolipoprotein A-I (ApoAI) is synthesized mainly by
the liver and the intestine as a preproprotein. After
cleavage of the pre- and pro-peptides, the mature pro-
tein (28 kDa, 243 amino acids) is secreted in the
plasma as a lipid-poor/lipid-free protein, which is the
main acceptor of cholesterol from artery wall cells [1].
It has been demonstrated that ABCA1 mediates the
secretion of cellular-free cholesterol and phospholipids
to ApoAI, its extracellular acceptor, to form nascent
high-density lipoproteins (HDLs) [2–4]. It emerged
that HDLs are dynamic entities undergoing remodel-
ing, lipolysis, and fusion that convert small particles to
large particles and vice versa [4]. ApoAI is the princi-
pal component (about 70% of proteins) of HDL,
nanoassemblies acting as carriers for cholesterol trans-
fer, via the plasma, from the periphery to steroidogenic
tissues, and to the liver for catabolism in the so called
reverse cholesterol transport [5,6].
A delicate balance between the lipid associated
(about 95%) and not associated (about 5%) state of
ApoAI accounts for its critical role as a lipid metabo-
lism regulator [7] and as a modulator of atherosclero-
sis. Although the molecular mechanism of the
atheroprotective action of ApoAI, as well as HDL bio-
genesis, is not fully understood, it is known that
ApoAI plays an antiatherogenic action in vivo, with a
protecting effect against cardiovascular diseases [8],
since atherosclerosis of hypercholesterolemic mice lack-
ing ApoAI [9,10] is counteracted by ApoAI transgenic
expression [11,12].
Key structural features for ApoAI functions are
conformational plasticity and flexibility, based on the
presence of 10 tandem of 11/22 residue repeats
(H1–H10) which form amphipathic lipid-binding a-
helices. Following the first crystal structure of lipid-
free human ApoAI, truncated at the N terminus (D1–
43) [13], a high-resolution (2.2 A) crystal structure was
obtained using a C-terminally truncated (D185–243)
form of the protein [14] to facilitate crystallization, the
C-terminal region being highly unfolded in solution.
The structure provided evidence that ApoAI forms a
half-circle dimer, in which two elongated antiparallel
helices connect two–four-helix bundles (Fig. 1A), each
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constituted by the N terminus of one chain (residues
1–121, helices I, II, III) and the C terminus of its part-
ner (residues 143–184, helix IV). However, it has to be
pointed out that the only high-resolution crystal struc-
ture so far available refers to a truncated form of the
protein, and therefore could be different from the real
solution form of the natural protein.
ApoAI and amyloidogenicity
Apolipoprotein A-I can be the causative agent of
acquired or familial amyloidoses. In the acquired, that
is, not inherited amyloidosis, the deposition of wild-
type full-length ApoAI occurs in arterial plaques
(atherosclerosis) [15,16]. This has to be ascribed to the
lower thermodynamic stability of lipid-free ApoAI
with respect to the HDL-bound protein. It has also to
be highlighted that oxidation of methionine residues of
lipid-free ApoAI has been identified as a primary
cause of protein destabilization and amyloid deposi-
tion in atherosclerotic plaques, where high levels of
oxidized lipid-free ApoAI were detected [17,18].
The first analysis of amyloid deposit composition in
localized forms of ApoAI-associated amyloidoses pro-
vided evidence of the presence of ApoAI-derived
N-terminal fragments in aortic amyloid deposits [19].
In the knee joint menisci of patients with knee
osteoarthritis, amyloid deposits were found to be
mainly constituted by ApoAI produced in situ by
chondrocytes [20].
Familial amyloidosis polyneuropathy (FAP),
instead, is associated with mutations in APOA1 gene.
About 20 natural mutations (Fig. 2) were mapped so
far as responsible for ApoAI systemic amyloidoses. In
patients carrying an amyloidogenic ApoAI variant
(AApoAI), amyloid deposition occurs overtime in
peripheral organs, such as heart, liver, kidneys, skin,
etc. [21].
No cure is available for these pathologies, being
organ transplantation the only possible treatment. In
AApoAI patients, ApoAI and HDL plasma levels are
generally lower than in normal subjects [22,23],
although this seems not to be the cause of cardiovas-
cular diseases [24]. ApoAI-decreased plasma levels
may be related to the lower amount of secreted amy-
loidogenic variants with respect to wild-type ApoAI,
as demonstrated for L75P-AApoAI overexpressed in
stably transfected human hepatic cells [25], as well as
for L75P- and L174S-AApoAI variants in transiently
transfected COS-7 cells [26].
The amyloidogenic mutations described so far in
patients, all heterozygous for the mutated gene, can be
divided in two groups: those located within the N-
terminal portion of the protein that is found in fibrils
(‘inside mutations’), and those located externally to
this region (‘outside mutations’) [23] (Fig. 2). Wher-
ever an amyloidogenic mutation is located, internally
or externally to the N-terminal region, amyloid fibrils
isolated ex vivo were found to be mainly constituted
by the N-terminal fragments of AApoAI, 80–100 resi-
due long. For instance, G26R point mutation, the first
amyloidogenic mutation discovered in ApoAI [27],
enhances the formation of fibrils containing ApoAI
fragment 1–83, whereas amyloid fibrils extracted from
patients carrying the first AApoAI outside mutation
identified (L174S) [28,29] were mainly constituted by
fragment 1–93. We performed a comparative analysis
of the aggregation propensity of eight recombinant iso-
forms of ApoAI 1–93 polypeptide, each carrying a
known amyloidogenic mutation of the N-terminal
region [30]. The data supported the hypothesis that ‘in-
side’ amyloidogenic mutations might enhance protein
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Fig. 1. (A) Ribbon representation of the crystal structure of lipid-free D185–243 human ApoAI dimer (PDB code 3R2P). (B) A model
proposed for the monomeric structure, as suggested by Mei and Atkinson [14].
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flexibility in the proximity of the putative cleavage site
releasing the N-terminal amyloidogenic domain [30],
consistently with Lagerstedt et al. [31]. We also pro-
vided evidence that an increased aggregation propen-
sity of isoforms of the N-terminal polypeptide is not
causative per se of amyloidogenesis [30].
Hallmarks of a pathogenic protein:
impact of mutations on protein
conformation
Nothing is known about the molecular mechanism
responsible for the release in vivo of a fibrillogenic
polypeptide from a full-length AApoAI variant, nor in
which context it occurs. In such an uncertain scenario,
any structural or functional difference between the nat-
ural protein and a pathological version of it would
represent an important clue to reveal mechanistic
aspects of the disease.
Interestingly, the majority of the amyloidogenic
mutations identified so far cluster in two regions: the
amino-terminus (residues 1–100) and within residues
170–178, which in ApoAI 3D structure are located in
the four-helix bundle domain and define a 3D hot spot
mutation site [14]. Based on sequence analyses, four hot
spots, corresponding to regions 14–22, 53–58, 69–72,
and 227–232, have been predicted [32]. Amyloidogenic
mutations occurring in these regions were proposed to
perturb the protein structure prompting aggregation via
the N-terminal region [32]. With the exception of 53–58,
these regions are mainly in a-helical structure, with
region 227–232 representing the primary lipid-binding
site of the protein. Noticeable is that ApoAI fibrillo-
genic polypeptides (residues from 1 to 80–100) encom-
pass all of the N-terminal predicted hot spots. To date,
from the analysis of some of the naturally occurring
full-length AApoAI variants identified so far, for exam-
ple, G26R, W50R, F71Y, L75P, A164S, L170P, R173P,
L174S, and L178H, interesting peculiarities of their con-
formational behavior have emerged.
Two hypotheses have been raised on the chronology
of the events occurring during fibrillogenesis. In one
case, ApoAI destabilization induced by amyloidogenic
mutations allows the cleavage of the full-length protein
and the release of the fibrillogenic polypeptide with
consequent aggregation in fibrils [23,29–31,33,34].
Alternatively, it has been hypothesized that destabiliza-
tion of AApoAI four-helix bundle promotes aggrega-
tion of the full-length variant, an event that precedes
the proteolytic cleavage releasing the N-terminal
region [32].
The elucidation of any structural differences between
AApoAI variants and the natural protein may be fun-
damental to elucidate molecular determinants that
make a protein amyloidogenic. From the large body of
data reported on amyloidogenic variant behavior with
respect to natural ApoAI, a picture emerges indicating
that the amyloidogenic phenotype is associated with
altered structural features, which are reported below
grouped into four main categories.
Effects of mutations on protein conformation
and lipid binding
Generally, amyloidogenic mutations induce protein
disorder, as demonstrated by CD analyses. Variants
F71Y-AApoAI and L170P-AApoAI showed a
decreased CD signal at 185–200 nm [32]; similar
effects, although much less evident, have been
described for G26R and W50R mutations [32,35]; in
the case of L75P-AApoAI and L174S-AApo-I, an
increased percentage of b-sheet structure has been
detected [36]; G26R, W50R, and F71Y mutations
cause marked changes in near-UV CD, while L170P
substitution is associated with the largest change with
more negative CD signals at 255–280 nm. Moreover,
studies by amide hydrogen–deuterium exchange
demonstrated that the G26R mutation destabilizes the
protein through the large region spanning residues
10–114, causing changes in protein structure and
dynamics [37]. As a consequence, the N-terminal helix
unfolds, inhibiting interactions within the N-terminal
helix bundle, which is destabilized.
Which are the consequences of an altered conforma-
tion? One should consider that all the above men-
tioned residues contribute in the native protein to the
L178H
ApoAI
70-72W50R
L60R
L64P
G26R
∆60-71/VT L90P
∆∆ K107
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R173P
A175P
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Q172P
Fig. 2. ApoAI mutations associated with systemic amyloidoses. In red, the mutations located within the N-terminal fibrillogenic region
(‘inside mutations’). In blue, the ‘outside mutations’. D, deletion mutations; fs, frameshift mutations.
4173FEBS Letters 590 (2016) 4171–4179 ª 2016 Federation of European Biochemical Societies
A. Arciello et al. Apolipoprotein A-I: the dual face of a protein
four-helix bundle stability. In particular, residue L75 is
located in the middle of the four-helix bundle, within
the short helix 70–76 that contributes to define the rel-
ative helical orientation in the bundle; G26 and W50
are also located in the middle of the bundle [38],
whereas F71, L170, and L174 are located at the ‘bot-
tom’ of it [32]. Therefore, it is conceivable that, associ-
ated with these mutations, and as a consequence of
the altered conformation, hydrophobic regions are
more exposed to the solvent than in the native protein,
as it has been described for L75P-AApoAI and L174S-
AApoAI, with a consequent increase in tryptophan
and 8-anilino-1-naphthalensulfonic acid (ANS) fluores-
cence emission [36]. A slight increase in ANS emission
was detected also for G26R-, W50R-, and F71Y-
AApoAI [35]. On the other hand, for L170P-AApoAI
a decrease in ANS emission was described, possibly
due to an increased order in the C terminus, a poten-
tial ANS-binding site. This is in line with a signifi-
cantly decreased deuteration of L170P-AApoAI in its
C-terminal tail (see below).
Generally, mutations do not promote dissociation of
the free protein from HDL [32], nor do they impair
the protein ability to bind to model phospholipids gen-
erating HDL-like complexes of unaltered size. How-
ever, mutations may decrease the lipoprotein stability
[35]. To this regard, G26R and W50R mutations
slightly reduce protein ability to recruit lipids to form
HDL [35], whereas larger destabilization occurs in the
case of the ‘outside’ mutation L170P. Mutation
L178H is responsible for an altered lipid-binding pro-
file [39]; similarly, R173P-AApoAI shows lower effi-
ciency to bind to phospholipid vesicles [40] and
A164S-AApoAI has lower binding affinity to lipids
[41].
Effects of mutations on protein flexibility and
stability
A generally decreased compactness is described for
AApoAI variants. This is at least in part related to an
increased flexibility of the protein chain, accompanied
by a reduced stability and loss of unfolding coopera-
tivity, as it has been observed for several AApoAI
variants [32,35–37]. Importantly, it has been pointed
out [35] that destabilization is not necessarily associ-
ated with misfolding, as demonstrated by some desta-
bilized, but not amyloidogenic, variants (e.g., Milano
variant) [42].
The DLS measurements of the hydrodynamic diam-
eter indicated that L75P-AApoAI is much less com-
pact than the wild-type protein and L174S-AApoAI.
Upon 7 days of incubation at 37 °C, L75P-AApoAI
and L174S-AApoAI diameter increased by about 50%
and 44%, respectively [14]. Mutation-driven protein
destabilization occurs at different degrees, being less
evident in case of G26R-AApoAI and W50R-AApoAI
variants (5 °C Tm), and more evident for L170P-
AApoAI (11 °C Tm), L174S-AApoAI (12 °C Tm),
and L75P-AApoAI (14 °C Tm) [31,32,35,36].
Again, a direct relationship between destabilization
and aggregation propensity cannot be envisaged.
Hydrogen–deuterium exchange studies revealed that
G26R mutation greatly increases solvent accessibility
and dynamics at the N terminus (first 90 residues), as
reported above [37]; L170P-AApoAI is less protected
from exchange at the major hot spot 14–22 among the
variants tested [35]. Mutations F71Y and W50R have
little effects on the C-terminal deuteration, while muta-
tion L170P induces a significant decrease in deuteration,
probably due to a more extensive packing of the protein
tail against the helix bundle, as reported above.
Effects of mutations on susceptibility to
proteases
It is conceivable that, as a direct consequence of the
decreased compactness and increased flexibility, sus-
ceptibility to proteases increases.
Enhanced susceptibility to protease cleavage has been
demonstrated in the N-terminal region of L75P-
AApoAI and L174S-AApoAI [36], to be related to N-
terminal destructuration and disorder. Exposure of a
proteolytic site at Y18, belonging to the major hot spot
14–22, was revealed in variants G26R-, L75P-, L174S-,
and L178H-AApoAI [31,36,39], while, in the case of
L174S-AApoAI, cleavages at R153 and Y166 occur, as
expected from MD simulations experiments which indi-
cated that region 153–166 is unstructured [36]. Similarly,
in L75P-AApoAI the accessibility of proteolytic sites at
E34 and F57 (the latter belonging to the minor hot spot
53–58), both hindered in the native protein, is the conse-
quence of the propagation of a local perturbation (helix
70–76) to the other predicted hot spots and the cause of
the decreased protein compactness.
Moreover, some mutations (e.g., L170P and G26R)
cause a disorder in the a-helical segment 83–93 by pos-
sibly exposing a proteolytic site that might be involved
in the release of the N-terminal region, while other
mutations (e.g., F71Y and W50R) do not [32]. Simi-
larly, in L174S-AApoAI, the C terminus seems to be
protected, as shown by the disappearance of the E223
cleavage site (exposed in the native protein and in
L75P-AApoAI), as well as by slower hydrolysis kinetic
at R188 and Y192 residues [36], thus suggesting that
conformational changes occurred in this region.
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Effects of mutations on aggregation propensity
A time-dependent increase of the b-sheet structure in
L75P-AApoAI and L174S-AApoAI has been reported
[36], similarly to G26R-AApoAI [39], whereas for
L178H-AApoAI an increase in the a-helical content
has been described over time, accompanied by the for-
mation of very short fibrillar structures [39]. Beaded
morphology of L75P-AApoAI fibrils well correlates
with the lower protein compactness, whereas the more
compact structure of L174S-AApoAI, combined with
its high flexibility, is in agreement with the formation
of thinner and longer fibrils.
Common features of amyloidogenic
mutations effects
A key feature of ApoAI is its conformational plasticity
and flexibility that make possible a prompt adaptation
of the protein to different environmental conditions.
ApoAI is, therefore, an optimal flexible scaffold for
lipidation/delipidation and cholesterol circulation,
since, due to its molten globule state, the protein is
able to easily switch from the presumed monomeric
state in the absence of lipids (about 5% of total
ApoAI) to an extended double belt-like conformation
in the lipid-bound state, with antiparallel a-helices
wrapped around the edge of nascent HDL. On the
other hand, the high protein flexibility is a key element
involved in pathological conditions, when an amy-
loidogenic mutation alters the protein architecture,
switching the dynamic state of the native protein
toward a ‘pathology-competent state’.
A wide range of effects can be ascribed to point muta-
tions. From a general point of view, the effects of muta-
tions can be summarized here as follows: (a) induction
of protein disorder with loss of protein compactness; (b)
destabilization of the N-terminal helix bundle; (c) expo-
sure of hydrophobic regions to the solvent; (d) increase
in protein flexibility and consequent susceptibility to
proteases; (f) altered lipid-binding profile.
The model recently proposed by Das et al. [32]
prompts that AApoAI amyloidogenic mutations per-
turb one of the four predicted hot spots of the protein
(14–22, 53–58, 69–72, and 227–232), with a consequent
full-length protein aggregation via the N-terminal
region. In particular, mutation-driven perturbations of
the native structure would allow the exposure of the
major amyloid hot spot 14–22, normally buried in the
middle of the four-helix bundle, triggering protein mis-
folding and aggregation. Thus, the paradigm proposed
is the following: conformational perturbation—expo-
sure of hot spots—protein aggregation.
However, some further considerations may be
added. First, a question can be raised: from the data
available so far on AApoAI variants can a more
general rule be drawn to classify the effects of muta-
tions on protein misfolding? To this regard, on the
basis of experimental evidence, it is tempting to pro-
pose that ‘inside’ and ‘outside’ mutations have a dif-
ferent impact on the protein, with internal mutations
destabilizing preferentially the N-terminal region, and
significantly altering protein conformation and com-
pactness, while external mutations, besides determin-
ing N-terminal destabilization, increase the overall
protein flexibility and induce a more pronounced
aggregation-competent state. As prototypes of inter-
nal and external mutations, respectively, L75P-
AApoAI is less compact, while L174S-AApoAI is
more flexible. In the natural protein, the flexible C-
terminal tail has low protection as it interacts weakly
with the helix bundle. In the presence of external
mutations (mainly clustered in the region 170–178),
the C-terminal tail is more protected and less
exposed, as demonstrated by L170P-AApoAI lower
deuteration kinetics, as well as by L174S-AApoAI
and L178H-AApoAI lower susceptibility of this
region to proteases with respect to the natural pro-
tein. Based on the observation that L170P mutation
greatly reduces protection from hydrogen–deuterium
exchange in the 83–93 region [32], it has been
hypothesized that an increased disorder in the well-
ordered a-helical segment 83–93 may facilitate prote-
olytic cleavage(s) in AApoAI variants.
A second consideration emerges from the model
proposed by Das et al. [32], suggesting that a
mutated protein is per se endowed with special molec-
ular features that make it amyloidogenic. At the same
time, intriguing but fully unexplained so far is the
observation that for some AApoAI variants a prefer-
ential fibril deposition in certain tissues occurs. As an
example, variant L75P-AApoAI is associated with a
hereditary systemic amyloidosis characterized by pref-
erential accumulation of fibrils in kidneys and liver
[43]. Instead, in the case of L174S-AApoAI, a pre-
dominant accumulation of fibrils in heart, skin, testes,
and larynx was observed [21]. The molecular bases of
the differential localization of amyloid fibrils are is
still unknown. Different environments (e.g., composi-
tion of cell membrane, extracellular matrix, soluble
molecules) might promote the unfolding/aggregation
pathway of a particular variant. If so, the physiologi-
cal context would be crucial and might play a key
role to determine the still unclear phenomenon of tis-
sue specificity of fibril deposition described for some
variants.
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A possible model
It has been proposed that, following binding to lipids,
ApoAI dimerization occurs via the opening of the
N-terminal four-helix bundle and the displacement of
the C-terminal region toward a second monomer and
vice versa to form an antiparallel helical ‘double belt’
on the HDL surface [14,44–46].
As monomers are metastable, they might switch
from a nonswapped to a swapped conformation, with
consequent dimerization, so that domain swapping
could be a natural consequence of the metastability of
the interconverting species. It is tempting to speculate
that such a flexible, aggregation prone protein, as it is
wild-type ApoAI, may escape aggregation via lipid
binding, which would promote dimer formation
through domain swapping.
In the model we propose (Scheme 1), lipids facilitate
monomer-to-dimer conversion, while AApoAI muta-
tions, perturbing the natural protein conformation
(dotted line structure in Scheme 1), alter its propensity
to dimerize, modifying consequently the physiologic
dynamic equilibrium between the interconverting spe-
cies. In case of an altered equilibrium between lipid-
bound and lipid-free ApoAI, not efficiently balanced
by ApoAI lipid-free clearance, the risk of aggregation
would dramatically increase. Indeed, studies on a
recombinant N-terminal fibrillogenic polypeptide (resi-
dues 1–93) demonstrated the effects of cholesterol, as
well as of zwitterionic, positively and negatively
charged liposomes in trapping the polypeptide in a
helical state, preserving it from aggregation [47]. A
similar effect of the lipid environment has also been
described for other amyloidogenic proteins, for
Interaction with cell
membrane and/or ECM
Protein destabilization
Opening of the cleft within
the four helix bundle
Less exposed
C-terminus
Alteration of flexible
linker 121–142 involved
in helix IV (143–184) 
domain swapping
N
C
ApoAI monomer
Lipid recruitment
HDL-bound ApoAI dimer
CN N’C’
Amyloidogenic
mutations
domain swapping
Increased
aggregation
propensity Tissue specific
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Metastable lipid-free monomer
prone to aggregation
Amyloid fibril
deposition
Lower lipid
binding affinityN
C
Scheme 1. Schematic representation of the monomeric and dimeric state of ApoAI. The conversion from monomer to dimer is facilitated
by lipid binding and achieved by domain swapping of the C-terminal tails between two ApoAI chains. Amyloidogenic mutations alter
structural and functional parameters of the protein, deviating the monomer-to-dimer balance toward unstable forms of the monomer prone
to aggregation. We hypothesize that a key factor responsible for tissue-specific deposition of ApoAI amyloidogenic variants is their
interaction with cell membrane and/or extracellular (ECM) matrix components.
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example, for a-synuclein, a protein with an
apolipoprotein lipid-binding motif [48].
To accomplish domain swapping, the C-terminal
region of a monomer has to displace from its initial
position and to shift toward the partner molecule by
breaking the intramolecular interactions within the
four-helix bundle and the reestablishing of similar con-
tacts with the N-terminal a-helices belonging to the
partner molecule. A lower exposition of the C-terminal
region to the solvent, as it has been found for L170P-,
L174S-, and L178H-AApoAI, could impair protein
interaction with lipids, and/or the C-terminal displace-
ment required for domain swapping, that is, it could
impair monomer-to-dimer conversion.
The alteration of protein conformation due to amy-
loidogenic mutations is able to propagate to the far sites
of the protein via the central hinge region (repeat H5)
that allows the interconversion between the monomer
and dimer. Therefore, a potentially key element is
expected to be the structural organization of the central
linker 121–142, and possibly its flanking regions, which
is highly flexible and probably facilitates the domain
swapping of helix IV (residues143–184) of the four-helix
bundle during monomer-to-dimer conversion. In this
regard, partial exposure to proteases of L75P-AApoAI
at residue K96, and of L174S-AApoAI at residue Y115
[36], as well as the destabilization of region 81–115 in
AApoAI-G26R, which allows proteolysis at residue 83
in vivo and consequent release of a fibrillogenic polypep-
tide [34,37], could be clues of the altered propensity to
undergo monomer-to-dimer conversion. Dynamic simu-
lation studies on the nonamyloidogenic ApoAI variants,
Milano and Paris [49], in which an arginine residue at
position 173 and 151, respectively, is mutated into a cys-
teine, suggest that in the lipid-bound protein the two
antiparallel strands of the central linker undergo reorga-
nization by a rotationally circular motion of the two
monomers to find proper registration, thus supporting
the intrinsic protein flexibility.
We hypothesize that in a cellular environment the
interactions of the protein with lipids may play a criti-
cal role in impeding, or in slowing down, the fibrillo-
genic process by entrapping the protein in a stable
helical structure unable to aggregate. Therefore, the
occurrence of 3D-domain swapping seems to have a
physiological significance. Membrane and extracellular
matrix components may regulate this interconversion,
altering the balance between aggregated and unaggre-
gated states of the protein. The impact of a different
membrane and/or extracellular matrix composition in
different tissues on protein aggregation evokes the fas-
cinating hypothesis that the combination of a particu-
lar conformational state (conformer) of the protein, as
well as its interaction with a particular class of lipids,
may be key elements to explain the tissue-specific
deposition observed for ApoAI amyloidogenic
isoforms.
In this scenario, the destabilization of protein hot
spots, although a central element for the comprehen-
sion of ApoAI amyloidogenesis, would be a condition
certainly necessary, but not per se sufficient to trigger
amyloidosis, as the recognition of specific molecules
(possibly lipids) on different cell types and in different
cell contexts could be decisive to make particular cell
types the natural target for the development of the
pathology.
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